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Dear Editor,
In their paper titled “Five-year Results of a Randomised
Clinical Trial of Endovenous Laser Ablation of the Great
Saphenous Vein with and without Ligation of the Sapheno-
femoral Junction”, Disselhoff et al. investigated whether
additional crossectomy is advantageous in laser treatment
of varicosity. The authors’ conclusion that crossectomy
does not improve the long-term outcome is incomprehen-
sible. Sclerotherapy was performed in 18 patients due to
insufficient lateral branches of the saphenofemoral junc-
tion. Sclerotherapy was most likely performed in those
patients who had not responded to laser therapy without
crossectomy; this therefore signified a disadvantage for the
surgical study arm.
A further point of criticism is the equation of so-called
neovascularisation and recurrence. The majority of the
neovascularisations established by duplex sonography are
clinically irrelevant and therefore insignificant phenomena
for the patient; they should not be equated with a recur-
rence. For instance, in a study performed by Hartmann
et al.1 spanning a mean follow-up period of 14 years, 78%
of the observed neorefluxes were clinically irrelevant
(<3 mm in diameter). In a study performed by Fischer2
spanning a mean follow-up period of 34 years, 63% of the
neorefluxes were clinically insignificant. The author made
no differentiation and equated neovascularisations with
recurrences, which was a disadvantage for the surgical
study arm and falsified the results of the study.
The authors’ results would probably have been entirely
different when non-responders of treatment who had
undergone sclerotherapy had also been regarded as recur-
rences, and clinically irrelevant neorefluxes had been
excluded from the evaluation.
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Response to Letter to the EditorDear Editor,
We have read the comments of your reader and would like
to answer as follows.
At 6 weeks, residual non-GSV varicose veins were
detected in 10 limbs (23%) in the EVLA with SFL group and in
eight limbs (18.6%) in the EVLA without SFL group. Acces-
sory saphenous veins were still visible in six limbs in each
group. So, there was no significant difference between the
two groups concerning additional sclerotherapy and treat-
ment of the non-GSV varicose veins did not influence the
primary outcome of the study.
As we described in the initial manuscript,1 the primary
outcome was duplex proven freedom of recurrent varicose
veins and not clinical recurrence. It is well documented
that duplex examination, performed by a vascular techni-
cian, is the golden standard in the evaluation of the venous
system and increases the homogeneity of the analysis.
The prevalence of neovascularization as a cause of recur-
rent varicose veins has been extensively debated in the liter-
ature and occurred in 20e60% of patients following surgery.
I agree that the clinical impact of neovascularization will be
more important if these vessels are in connection with
a refluxing residual GSV trunk. In this study, the rate of type 1a
recurrence 5 year after EVLAwith SFJ ligationwas zero and only
5 patients of the 14 type 1c recurrences were sufficiently
symptomatic to warrant consideration of additional treatment.
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